- Home
- GHRS vs KALV Comparison
GHRS vs KALV Comparison
Compare GHRS & KALV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GHRS
- KALV
- Stock Information
- Founded
- GHRS 2018
- KALV N/A
- Country
- GHRS Ireland
- KALV United States
- Employees
- GHRS N/A
- KALV N/A
- Industry
- GHRS Biotechnology: Pharmaceutical Preparations
- KALV Biotechnology: Pharmaceutical Preparations
- Sector
- GHRS Health Care
- KALV Health Care
- Exchange
- GHRS Nasdaq
- KALV Nasdaq
- Market Cap
- GHRS 774.1M
- KALV 796.4M
- IPO Year
- GHRS 2021
- KALV N/A
- Fundamental
- Price
- GHRS $13.11
- KALV $11.35
- Analyst Decision
- GHRS Strong Buy
- KALV Strong Buy
- Analyst Count
- GHRS 9
- KALV 8
- Target Price
- GHRS $29.33
- KALV $26.43
- AVG Volume (30 Days)
- GHRS 319.1K
- KALV 1.4M
- Earning Date
- GHRS 11-13-2025
- KALV 09-11-2025
- Dividend Yield
- GHRS N/A
- KALV N/A
- EPS Growth
- GHRS N/A
- KALV N/A
- EPS
- GHRS N/A
- KALV N/A
- Revenue
- GHRS N/A
- KALV $1,426,000.00
- Revenue This Year
- GHRS N/A
- KALV N/A
- Revenue Next Year
- GHRS N/A
- KALV $209.38
- P/E Ratio
- GHRS N/A
- KALV N/A
- Revenue Growth
- GHRS N/A
- KALV N/A
- 52 Week Low
- GHRS $6.72
- KALV $7.30
- 52 Week High
- GHRS $20.50
- KALV $17.28
- Technical
- Relative Strength Index (RSI)
- GHRS 47.63
- KALV 38.61
- Support Level
- GHRS $12.26
- KALV $10.69
- Resistance Level
- GHRS $13.65
- KALV $12.00
- Average True Range (ATR)
- GHRS 0.75
- KALV 0.57
- MACD
- GHRS -0.08
- KALV -0.07
- Stochastic Oscillator
- GHRS 31.37
- KALV 25.34
About GHRS GH Research PLC
GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment for depression. Its initial focus is on developing novel and proprietary mebufotenin therapies for the treatment of patients with Treatment-Resistant Depression, or TRD. Its portfolio currently includes GH001, a proprietary inhalable mebufotenin product candidate, and GH002, a proprietary intravenous mebufotenin product candidate. The group has only a single segment: Research and Development.
About KALV KalVista Pharmaceuticals Inc.
KalVista Pharmaceuticals Inc is a pharmaceutical company developing and delivering oral therapies for individuals affected by rare diseases with unmet needs. The company applies its knowledge in the kallikrein-kinin system (KKS) and oral drug discovery to develop small-molecule protease inhibitor medicines to address the needs of patients with diseases driven by plasma kallikrein and Factor XIIa. Its FDA-approved product EKTERLY (sebetralstat) is a novel, orally delivered, small-molecule plasma kallikrein inhibitor for the treatment of acute attacks of hereditary angioedema (HAE) in adult and pediatric patients aged twelve years and older.